Search research articles
Contact Us
Filters
Showing results (391-400 of 471) with videos related to
Page
of 48
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2018
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Kaiji Fan, Cathrin Ritter, Paul Nghiem, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC
David R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Journal of Alzheimer'S Disease : JAD
|
July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease
Charles B Malpas, Lucy Vivash, Sila Genc, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 30, 2019
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
David Taïeb, Rodney J Hicks, Elif Hindié, et al.
The Journal of Pathology
|
December 30, 2014
The genomic landscape of phaeochromocytoma
Aidan Flynn, Diana Benn, Roderick Clifton-Bligh, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
Amir Iravani, Medhat M Osman, Alison M Weppler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors
Jeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
The Lancet. Oncology
|
May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S Hofman, John Violet, Rodney J Hicks, et al.
Journal for Immunotherapy of Cancer
|
October 16, 2020
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
Alison M Weppler, Andrew Pattison, Prachi Bhave, et al.
Page
of 48
Search research articles
Search
Showing results (391-400 of 471) with videos related to
Sort By:
Page
of 48
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2018
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Kaiji Fan, Cathrin Ritter, Paul Nghiem, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC
David R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Journal of Alzheimer'S Disease : JAD
|
July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease
Charles B Malpas, Lucy Vivash, Sila Genc, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 30, 2019
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
David Taïeb, Rodney J Hicks, Elif Hindié, et al.
The Journal of Pathology
|
December 30, 2014
The genomic landscape of phaeochromocytoma
Aidan Flynn, Diana Benn, Roderick Clifton-Bligh, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
Amir Iravani, Medhat M Osman, Alison M Weppler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors
Jeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
The Lancet. Oncology
|
May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S Hofman, John Violet, Rodney J Hicks, et al.
Journal for Immunotherapy of Cancer
|
October 16, 2020
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
Alison M Weppler, Andrew Pattison, Prachi Bhave, et al.
Page
of 48